Pharmaceutical Patents, Paragraph IV, and Pay-for-Delay: The Landscape of Drung Patent Litigation and the Lessons Provided for the Recently Passed Biosimilar Approval Pathway
Intellectual Property Brief
Part of the Intellectual Property Law Commons